ROG

Roche said phase III data supports benefit/risk profile of Hemlibra

Credit: REUTERS/Peter Nicholls

Analysis of data from a phase IIIb clinical study further supports the benefit/risk profile of Hemlibra in patients with haemophilia A, with no new safety signals identified, Swiss drugmaker Roche Holding said on Monday.

ZURICH, July 19 (Reuters) - Analysis of data from a phase IIIb clinical study further supports the benefit/risk profile of Hemlibra in patients with haemophilia A, with no new safety signals identified, Swiss drugmaker Roche Holding ROG.S said on Monday.

Hemlibra also continued to demonstrate effective bleed control, with nearly 83% of participants achieving zero treated bleeds, Roche said.

(Reporting by Michael Shield, editing by Silke Koltrowitz)

((silke.koltrowitz@thomsonreuters.com; +41 41 528 3638;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ROG

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More